{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","spread":"22.7","value":"66.6"},{"groupId":"OG001","spread":"22.5","value":"66.8"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"291"},{"groupId":"OG001","value":"274"}],"units":"Participants"}],"title":"Global Health Status - Baseline"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"22.2","value":"-0.2"},{"groupId":"OG001","spread":"17.8","value":"2.0"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"245"},{"groupId":"OG001","value":"218"}],"units":"Participants"}],"title":"Global Health Status - Week 4"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"24.2","value":"2.9"},{"groupId":"OG001","spread":"20.6","value":"1.1"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"238"},{"groupId":"OG001","value":"187"}],"units":"Participants"}],"title":"Global Health Status - Week 10"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"23.1","value":"1.8"},{"groupId":"OG001","spread":"23.7","value":"-1.0"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"106"},{"groupId":"OG001","value":"135"}],"units":"Participants"}],"title":"Global Health Status - Week 16"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"24.6","value":"4.3"},{"groupId":"OG001","spread":"22.8","value":"-0.5"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"165"},{"groupId":"OG001","value":"50"}],"units":"Participants"}],"title":"Global Health Status - Week 20"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"25.3","value":"4.0"},{"groupId":"OG001","spread":"13.0","value":"-0.6"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"193"},{"groupId":"OG001","value":"29"}],"units":"Participants"}],"title":"Global Health Status - Week 24"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"25.1","value":"6.4"},{"groupId":"OG001","spread":"17.2","value":"-3.7"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"150"},{"groupId":"OG001","value":"9"}],"units":"Participants"}],"title":"Global Health Status - Week 36"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"24.9","value":"7.1"},{"groupId":"OG001","spread":"12.7","value":"-2.8"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"92"},{"groupId":"OG001","value":"3"}],"units":"Participants"}],"title":"Global Health Status - Week 48"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"25.0","value":"8.1"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"62"},{"groupId":"OG001","value":"0"}],"units":"Participants"}],"title":"Global Health Status - Week 60"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"26.5","value":"6.6"},{"comment":"Insufficient number of participants to calculate SD.","groupId":"OG001","spread":"NA","value":"-8.3"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"54"},{"groupId":"OG001","value":"1"}],"units":"Participants"}],"title":"Global Health Status - Week 72"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"26.7","value":"9.8"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"39"},{"groupId":"OG001","value":"0"}],"units":"Participants"}],"title":"Global Health Status - Week 84"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"18.2","value":"9.0"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"26"},{"groupId":"OG001","value":"0"}],"units":"Participants"}],"title":"Global Health Status - Week 96"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"13.7","value":"7.6"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"11"},{"groupId":"OG001","value":"0"}],"units":"Participants"}],"title":"Global Health Status - Week 108"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"25.5","value":"13.9"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"3"},{"groupId":"OG001","value":"0"}],"units":"Participants"}],"title":"Global Health Status - Week 120"}],"denoms":[{"counts":[{"groupId":"OG000","value":"304"},{"groupId":"OG001","value":"304"}],"units":"Participants"}],"description":"The EORTC QLQ-C30 is a questionnaire used to assess the quality of life in cancer patients. It includes a global health status score, which is measured on a 4-point Likert scale: 1 = not at all, 2 = a little, 3 = quite a bit, and 4 = very much. Responses are combined and converted to scores ranging from 0 to 100. A high score for global health status or health-related quality of life (HRQoL) indicates a high overall HRQoL.","dispersionType":"Standard Deviation","groups":[{"description":"Participants received Nivolumab 360 mg in combination with Standard of Care treatment every 3 weeks (Q3W) for up to 6 cycles followed by Nivolumab monotherapy 480 mg every 4 weeks (Q4W) - Sub-study","id":"OG000","title":"Treatment 3"},{"description":"Participants received Standard of Care treatment every three weeks (Q3W) for up to 6 cycles - Sub-study","id":"OG001","title":"Treatment 4"}],"paramType":"MEAN","populationDescription":"All Randomized Participants - Sub-study","reportingStatus":"POSTED","timeFrame":"At Baseline, Week 4, Week 10, Week 16, Week 20, Week 24, Week 36, Week 48, Week 60, Week 72, Week 84, Week 96, Week 108, and Week 120","title":"Change From Baseline in the European Organization for Research and Treatment of Care Quality-of-Life Questionnaire (EORTC QLQ-C30) Global Health Status Score for Sub-study","type":"SECONDARY","unitOfMeasure":"Score on a Scale"}